News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Continue Reading Previous Aleafia Health to Announce Fiscal Year 2022 Fifth Quarter and Year End Results – UpdateNext Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Related Stories News TMX Group Thanksgiving Holiday Market Closures News TIPAK Marks Path to Leadership in Packaging Solutions Following Listing on SET News Chervon Names Daniel L. Abbott Director of Sales – Western U.S.A. News Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts News Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon Canada News Pelican Announces Appointment of Nino Di Teodoro to Its Board of Directors
